# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Dyskinesia, Drug Induced

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 11 results.
Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease
Status: Recruiting
Last Changed: Aug 29, 2018
First Received: Nov 28, 2017
Disease(s): Dyskinesia, Drug-Induced, Parkinson Disease
Intervention(s): Repetitive transcranial magnetic stimulation
Locations: Danish Research Centre for Magnetic Resonance, Hvidovre, Capital Region, Denmark
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
Status: Not yet recruiting
Last Changed: Jun 17, 2019
First Received: Jun 17, 2019
Disease(s): Dyskinesia, Drug-Induced, Parkinson Disease
Intervention(s): Safinamide Methanesulfonate 150mg, Safinamide Methanesulfonate 100mg, Safinamide Methanesulfonate matching placebo
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
Status: Recruiting
Last Changed: Mar 15, 2019
First Received: Nov 04, 1999
Disease(s): Chorea, Drug Induced Dyskinesia, Movement Disorder, Muscular Disease, Tic Disorder
Intervention(s): Botulinum Toxin
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
Status: Recruiting
Last Changed: Mar 22, 2019
First Received: Apr 11, 2018
Disease(s): Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism
Intervention(s): Varenicline
Locations: Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States
Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
Status: Recruiting
Last Changed: Nov 22, 2017
First Received: Feb 23, 2017
Disease(s): Tardive Dyskinesia
Locations: Neurocrine Clinical Site, Little Rock, Arkansas, United States
Neurocrine Clinical Site, Anaheim, California, United States
Neurocrine Clinical Site, Anaheim, California, United States
Neurocrine Clinical Site, Long Beach, California, United States
Neurocrine Clinical Site, Los Gatos, California, United States
... and 30 other locations.
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
Status: Recruiting
Last Changed: Mar 27, 2019
First Received: Mar 27, 2019
Disease(s): Tardive Dyskinesia (TD)
Intervention(s): Valbenazine, Placebo oral capsule
Locations: Neurocrine Clinical Site, Little Rock, Arkansas, United States
Neurocrine Clinical Site, Anaheim, California, United States
Neurocrine Clinical Site, Anaheim, California, United States
Neurocrine Clinical Site, Costa Mesa, California, United States
Neurocrine Clinical Site, Escondido, California, United States
... and 31 other locations.
Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia
Status: Recruiting
Last Changed: Apr 26, 2019
First Received: Sep 19, 2017
Disease(s): Tardive Dyskinesia, Antipsychotic Agents
Intervention(s): Pyridoxine, Placebo
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
Status: Recruiting
Last Changed: Jun 17, 2019
First Received: Jun 05, 2017
Disease(s): Tardive Dyskinesia
Intervention(s): MT-5199, Placebo
Locations: Aichi Psychiatric Medical Center, Aichi, Japan
Hotei Hospital, Aichi, Japan
Mikawa Hospital, Aichi, Japan
Okehazama Hospital Fujita Kokoro Care Center, Aichi, Japan
Akita City Hospital, Akita, Japan
... and 78 other locations.
Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia
Status: Recruiting
Last Changed: Apr 13, 2018
First Received: Apr 13, 2018
Disease(s): Tardive Dyskinesia
Intervention(s): Active tDCS, Sham tDCS
Locations: Suzhou Psychiatric Hospital, Suzhou, Jiangsu, China
Suzhou, Suzhou, Jiangsu, China
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
Status: Recruiting
Last Changed: Nov 06, 2018
First Received: Oct 08, 2018
Disease(s): Tardive Dyskinesia (TD)
Intervention(s): Valbenazine, Placebo oral capsule
Locations: Neurocrine Clinical Site, Anaheim, California, United States
Neurocrine Clinical Site, Glendale, California, United States
Neurocrine Clinical Site, Norwalk, California, United States
Neurocrine Clinical Site, Oceanside, California, United States
Neurocrine Clinical Site, San Bernardino, California, United States
... and 12 other locations.